Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.65 |
| ▸ | NPC1 | O15118 | 7/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.65 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.62 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.62 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3019067 | 0.96 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2PARP15PARP10 | |
| SCHEMBL417903 | 0.87 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2LMNAMAPT | |
| SCHEMBL417902 | 0.87 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2LMNAMAPT | |
| SCHEMBL565748 | 0.87 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2LMNAMAPT | |
| SCHEMBL13937031 | 0.86 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2LMNAMAPT | |
| SCHEMBL30969251 | 0.83 | TDP1 (0.57) | RAB9ANPC1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL2813862 | 0.83 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2LMNAMAPT | |
| SCHEMBL16561437 | 0.83 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2LMNAMAPT | |
| SCHEMBL2813859 | 0.83 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2LMNAMAPT | |
| SCHEMBL4656658 | 0.83 | PARP10 (0.66) | RAB9ANPC1SMN1; SMN2PARP15PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204224-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS | VERNALIS R & D LIMITED (GB) | 2010-08-12 | — | — | US | disclosed |
| EP-1910374-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS | Vernalis (R&D) Limited (GB) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007007069-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS | VERNALIS (R & D) LIMITED (GB) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204224-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS | SCN1B, SCN2B, SCN1A | RAB9A 1757/4885NPC1 916/4885SMN1; SMN2 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.